Overview / Abstract: |
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with high disease burden and poor outcomes despite androgen deprivation therapy. This activity by Neeraj Agarwal, MD, provides strategies for germline genetic testing and somatic testing to best inform treatment. Poly (ADP-ribose) polymerase (PARP) inhibitor therapy provides a unique approach to treatment. Dr. Agarwal reviews safety and efficacy findings from recent clinical trials for the two PARP inhibitors, olaparib and rucaparib, approved in the United States for mCRPC. He also shares observations regarding PARP inhibitors in combination with other therapies. |
Expiration |
Jun 15, 2022 |
Discipline(s) |
Physician CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
0.5 AMA PRA Category 1 Credit™. |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
FACULTY REVIEWER |
Activity Specialities / Related Topics |
Oncology / Cancer / Radiation Therapy |
Sponsors / Supporters / Grant Providers |
This educational activity is supported by educational grants from AstraZeneca and Merck & Co., Inc. |
Keywords / Search Terms |
Annenberg Center for Health Sciences at Eisenhower Prostate Cancer • PARP inhibitor mechanism of action • Olaparib clinical trials • Rucaparib clinical trials • PARP inhibitor combination therapy Free CE CME |